Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review
Leuk Lymphoma
.
2022 May;63(5):1242-1245.
doi: 10.1080/10428194.2022.2060505.
Epub 2022 May 5.
Authors
Andrea C Lo
1
2
3
,
Caroline L Holloway
2
3
4
,
Kerry J Savage
3
5
6
,
Laurie H Sehn
3
5
6
,
Daniel F Worsley
7
,
Joseph M Connors
3
5
6
,
Tom Pickles
1
2
3
Affiliations
1
Department of Radiation Oncology, British Columbia Cancer Vancouver, Vancouver, Canada.
2
Department of Surgery, University of British Columbia (UBC), Vancouver, Canada.
3
BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada.
4
Department of Radiation Oncology, British Columbia Cancer Victoria, Victoria, Canada.
5
Department of Medical Oncology, British Columbia Cancer, Vancouver, Canada.
6
Department of Medicine, University of British Columbia (UBC), Vancouver, Canada.
7
Department of Nuclear Medicine, Vancouver General Hospital, Vancouver, Canada.
PMID:
35514121
DOI:
10.1080/10428194.2022.2060505
No abstract available
Publication types
Letter
MeSH terms
Humans
Lymphoma, B-Cell, Marginal Zone* / diagnosis
Lymphoma, B-Cell, Marginal Zone* / radiotherapy
Orbital Neoplasms* / diagnosis
Orbital Neoplasms* / radiotherapy
Radioimmunotherapy
Retrospective Studies
Rituximab
Substances
Rituximab